SVB Securities raised the price target for the Ideaya Biosciences Inc (NASDAQ:IDYA) stock to “an Outperform”. The rating was released on August 08, 2023, according to finviz.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Ideaya Biosciences Inc (NASDAQ:IDYA) raised 1.44% to close Friday’s market session at $30.37, higher as compared to yesterday’s close. The stock price fluctuated between $29.7701 and $30.7775 throughout the trading session with the volume trading being 1165642 shares, which represented a significant variation when compared to the three months average volume of 732.06K shares. The firm’s stock price fluctuated 3.33% within the last five trades and 17.12% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 39.50% in the last 6 months and 12.82% was added to its value over the previous 3 months. IDYA stock is trading at a margin of 7.53%, 9.91% and 35.80% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, IDYA deals in the Healthcare domain. The stock is trading -2.75 percent below its 52-week high and 128.52 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 81.4. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Ideaya Biosciences Inc’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at -506.54 percent and the profit margin is -439.48 percent, and the company has reported a gross margin of 85.09 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $1.90 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 80.76 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 3.50, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 13.24 percent of Ideaya Biosciences Inc shares are owned by insiders, and 83.76 percent are held by financial institutions. Throne Jason, the Chief Legal Officer at Ideaya Biosciences Inc (IDYA) has sold 5,163 shares of firm on Nov 03 at a price of $30.09 against the total amount of $0.16 million. In another inside trade, Throne Jason, Chief Legal Officer of Ideaya Biosciences Inc (NASDAQ:IDYA) sold 1,000 shares of the firm on Sep 12 for a total worth of $30005.0 at a price of $30.00. An inside trade which took place on Sep 05, Chief Legal Officer of Ideaya Biosciences Inc Throne Jason sold 1,737 shares of firm against total price of $52160.0 at the cost of $30.03 per share.